This article is more than 5 years old. Information may no longer be current.
Restasis Multidose covered in Canada
Click Here to Manage Email Alerts
Allergan announced that Restasis Multidose 0.05% has received approval from Health Canada.
“Restasis Multidose exemplifies Allergan’s commitment to innovation and customer responsiveness,” Carmen Enciu, MD, medical director and Canadian chief medical office director for Allergan Canada, said in a press release. “Through our open science model, we strive to deliver advancements to help improve patient care, such as the new multidose bottle.”
Restasis Multidose (cyclosporine ophthalmic emulsion) was designed with patented valve and air filter technology and offers the same preservative-free formulation as Restasis while providing dry eye sufferers with an easy-to-use multidose bottle, the company said in a press release.
Restasis helps increase tear production, according to the release, and can alleviate common dry eye symptoms, such as dryness, grittiness, burning and stinging. According to the release, it can also improve performance of daily activities, including driving, reading and using a computer. Additionally, when compared to packages of single-use vials, Allergen said the new multidose bottle uses less plastic.